Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
Status:
Completed
Trial end date:
2021-04-05
Target enrollment:
Participant gender:
Summary
The purpose is to demonstrate the efficacy of low-dose interleukin 2 (Ld-IL2) administration
in improving clinical course and oxygenation parameters in patients with SARS-CoV2-related
ARDS.